Together, we can turn affordability into genuine health gains
Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet licensed by the MHRA or EMA, with Phase 2 data suggesting significant weight reduction but Phase 3 confirmation still required
If you already feel nauseous, bloated, lightheaded, or overly full, drinking alcohol may make those symptoms worse
Regulatory callout: Retatrutide is investigational and not FDA-approved
5 Feb 1998
53 Ecological Momentary Assessment and Cue-Elicited Drug Craving as Primary End Points: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Testing the Efficacy of a GLP-1 RA in Opioid Use Disorder